Monitor Phase 1 data for CITY-FXI expected late 2026 and CITY-RBP4 trial initiation; IPO pricing and post-offer float will determine near-term trading dynamics.
Executive Summary
City Therapeutics, a clinical-stage RNAi biotech founded in July 2023, filed its S-1/A for an IPO of 9,722,222 shares at an estimated $17-$19 range. The company has no approved products, an accumulated deficit of $142.5M as of June 30, 2026, and expects net proceeds of ~$158.3M to fund pipeline programs (CITY-FXI, CITY-RBP4, CITY-TFR2) and platform development into late 2028.
Key Financial Metrics
Key Facts
- IPO of 9,722,222 shares at estimated $17-$19 per share; net proceeds ~$158.3M at midpoint.
- Clinical-stage RNAi biotech; lead candidate CITY-FXI in Phase 1; no approved products.
- Net losses of $27.8M (2024), $58.5M (2025), $53.4M (H1 2026); accumulated deficit $142.5M.
- Cash and equivalents $172.1M as of June 30, 2026; IPO proceeds extend runway into late 2028.
- Collaborations with Bausch + Lomb and Biogen; licensed IP from Ohio State Innovation Foundation.
Financial Impact
IPO raises ~$158.3M net; funds allocated: $30M CITY-FXI, $20M CITY-RBP4, $40M CITY-TFR2, $70M platform.
Risk Factors
- No approved products; early clinical stage with high development risk.
- Substantial additional capital needed beyond IPO proceeds.
- Novel technology platform may not yield marketable products.
- Competition from established RNAi and anticoagulant players.
- Dependence on third-party manufacturers and CROs.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001104659-26-114815 |
| Document: tm2619715d9_ex10-2.htm | 0001104659-26-114815 |
| Document: tm2619715d9_ex1-1.htm | 0001104659-26-114815 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13D | $20.79 | awaiting T+5 | — | $20.86 (+0.34%) |
Oct 26, 2026 1d ago | SC 13G | $20.79 | awaiting T+5 | — | $20.86 (+0.34%) |
Oct 22, 2026 5d ago | SC 13G | $20.77 | awaiting T+5 | — | $20.86 (+0.43%) |
Oct 19, 2026 8d ago | Insider Cluster | $20.83 $20.86 | ▲ +0.14% | ▲ +0.06% | $20.86 (+0.14%) |
Oct 19, 2026 8d ago | Press Release | $20.83 $21.19 | ▲ +1.73% | ▲ +1.70% | $20.86 (+0.14%) |
Oct 16, 2026 11d ago | 424B4 | $21.46 $20.79 | ▼ −3.12% | ▼ −2.98% | $20.86 (−2.80%) |
Oct 16, 2026 11d ago | EFFECT | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 11d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 11d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 11d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers